emeset 4 ml 2 mg/ml soluţie injectabilă/perfuzabilă
cipla uk limited - ondansetronum - soluţie injectabilă/perfuzabilă - 4 ml 2 mg/ml
nebivolol stada comprimate 5 mg
stada arzneimittel ag - nebivololum - comprimate - 5 mg
zitazonium comprimate 10 mg
egis pharmaceuticals plc - tamoxifenum - comprimate - 10 mg
flucetamol 120 mg 5 ml 120 mg/5 ml sirop
sc flumed-farm srl - paracetamolum - sirop - 120 mg/5 ml
flucetamol 120 mg 5 ml 120 mg/5 ml sirop
sc flumed-farm srl - paracetamolum - sirop - 120 mg/5 ml
metronidazol solutie perfuzabila 5 mg/ml
iuria-farm srl - metronidazolum - solutie perfuzabila - 5 mg/ml
metronidazol a solutie perfuzabila 5 g/l + 55 g/l
infomed fluids srl, sc - metronidazolum + glucoză - solutie perfuzabila - 5 g/l + 55 g/l
metronidazol b solutie perfuzabila 5 g/l
infomed fluids srl, sc - metronidazolum - solutie perfuzabila - 5 g/l
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.
dexdor 100 mcg/ml concentrat pentru soluţie perfuzabilă
orion corporation - dexmedetomidinum - concentrat pentru soluţie perfuzabilă - 100 mcg/ml